Psychopharmacological Perspectives and Diagnosis of Substance Use Disorder by Duresso, Samson
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books












A considerable body of research has accumulated over several decades and 
altered the current understanding of substance use and its effects on the brain. 
This knowledge has improved the perception of the disease of addiction and has 
opened the door to new ways of thinking about diagnosis, prevention, and treat-
ment of substance use disorders. The purpose of the current chapter is to briefly 
outline and summarize the major psychopharmacological framework underlying 
substance use disorder (SUD) and the factors that involve in the transformation 
of some people from recreational use or misuse of alcohol or drugs to SUD. The 
chapter explains the overall neurocircuitry theories of the addiction cycle: binge/
intoxication, withdrawal/negative affect, and preoccupation/anticipation. It briefly 
discusses how psychoactive substances produce changes in brain functioning that 
facilitate the development of addiction and contribute to craving which eventually 
leads to relapse. The chapter also deals with similarities and differences among 
various classes of addictive substances in their effects on the brain and behavior 
and briefly describes the main risk factors that involve SUD. Finally, an attempt is 
made to briefly discuss the major DSM 5 based behavioral criteria that involve SUD, 
corresponding to the most abused substances worldwide.
Keywords: Addiction, Substance use, addiction cycle, substance use disorder, 
Neurocircuitry, Reward system, Neuroadaptation, Incentive-Sensitization,  
Incentive-Salience, DSM-5 criteria
1. Introduction
Addiction is the recurrent use of mood-altering substances, such as alcohol 
and other drugs, despite their adverse health and psychosocial consequences. The 
interplay among genetic, psychosocial, and environmental factors influences the 
development and manifestations of the disorder [1]. For some individuals, becom-
ing physiologically dependent on a certain substance is likely to be a developmental 
process. Individuals may start with a positive attitude towards a substance, begin 
to practice using it, become regular users, progress to being heavy users and finally 
become dependent on it. While developing a positive attitude towards a certain 
substance, for instance, cigarettes and beginning to experiment with it, may be 
strongly related to exposures to smoking by other family members [2], becoming 
heavy smoker, on the other hand, is more strongly related to frequent exposures to 
peer smoking and being able to access cigarettes readily [3].
Addictions - Diagnosis and Treatment
2
Addiction, which was once viewed mainly as a moral failing or character fault, 
is now considered as a chronic illness of the brain characterized by clinically 
significant impairments in health, social function, and involuntary control over 
drug use [4, 5]. Although the mechanisms may be different, addiction, like most 
physiological disorders, is chronic, subject to relapse, and influenced by genetic, 
developmental, psychosocial, and environmental factors. Addictive substances 
exert significant influences on the brain that may affect thoughts, emotions, and 
behaviors. Substances of abuse have powerful effects on the brain and produce 
euphoria (extreme pleasure) which provokes users to seek those substances repeat-
edly despite the risks for significant harms.
As individuals continue to misuse alcohol or other substances, neuroadapta-
tions occur due to progressive changes in the structure and function of the brain. 
Neuroadaptation compromises brain function and eventually results in the transi-
tion of an individual from controlled, occasional substance use to chronic misuse, 
which can be difficult to control. These brain changes may persist long after an 
individual stops and produce a continuous or periodic craving for the substance that 
can lead to relapse: More than 60 percent of people treated for a certain substance 
use disorder experience relapse within the first year after completion of treatment 
[6], and some may remain at increased risk of relapse for many years.
Much of our knowledge about the effects of substance use and misuse on the 
brain as well as the development of addiction comes from the study of laboratory 
animals. Neurobiological studies in animals have examined both the immediate 
effects (acute impact) of addictive substance in the brain right after ingestion and 
the long term or chronic impact of drug use to understand, at the most basic level, 
the mechanisms through which substance use alters brain structure and function 
and facilitates the transition from occasional use to misuse, addiction, and relapse. 
Although the animal models do not fully reflect the human experience, animal 
studies help researchers investigate addiction and related behavioral changes 
under highly controlled conditions that may be difficult or unethical to replicate in 
humans [7].
To supplement the work in animals, a growing body of substance use research 
has been conducted with humans. The use of brain-imaging technologies, such as 
magnetic resonance imaging (MRI) and positron emission tomography (PET) scans 
for studying the effects of alcohol and drugs on the human brain have significantly 
advanced the current knowledge of SUD by allowing researchers to see inside the 
living human brain. Using these technologies, researchers can investigate and 
characterize the biochemical, functional, and structural changes in the brain which 
result from addictive substances and find out how such changes may ultimately 
contribute to substance use, misuse, and addiction [8]. Animal and human studies 
are integrated and inform each other for a more complete picture of the neurobiol-
ogy of addiction [9].
The structural and functional changes caused by using drugs can be long-lasting 
and can lead to harmful behaviors seen in individuals who continued to abuse 
drugs. Although the initial decision to try a drug of choice is mostly voluntary, 
eventually, as drug abuse takes over or an individual transforms from occasional 
user to heavy user, his/her ability to exert self-control may become seriously 
affected. Brain imaging studies conducted on drug-addicted individuals typically 
revealed that physical changes have been observed in the areas of the brain that 
are critical to judgment, decision making, learning, memory, and self-control. 
Scientists believe that these changes alter the way the brain works and may help 
explain the compulsive and destructive behaviors of addiction [10].
Susceptibility for addiction varies from individual to individual as for any other 
diseases. This depends on the amount and level of risk factors a person has. The 
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more the risk factors the greater the chance that taking drugs will lead to abuse and 
addiction. No single factor determines whether a person will become addicted to 
drugs. The overall risk for addiction is influenced by the biological makeup of the 
individual including sex or ethnicity, developmental stage, and the surrounding 
social environment such as home, school, and the neighborhood.
Individuals with mental disorders are at greater risk of drug abuse and addiction 
than the general population [11]. A growing body of research reveals that SUDs and 
many psychiatric disorders share comparable neural mechanisms. There are several 
clinical resemblances and symptom overlaps between SUDs and affective disorders 
[12]. Epidemiological studies revealed that co-occurring substance abuse and 
psychiatric problems are common in clinical practice. SUDs and a variety of mental 
illnesses have similar changes in the dopamine-mediated reward system as well as 
different neurotransmitter systems such as GABA, and serotonin [10]. According to 
recent findings from neuroimaging research, similar abnormalities in frontal-limbic 
brain circuitry are implicated in SUDs and depressive disorders. Individuals with 
SUDs have been found to have lower frontal metabolism and anterior cingulate acti-
vation [13, 14]. Depressive symptoms are typically observed after acute and chronic 
drug withdrawal due to anomalies in the CRF and HPA axis, as well as alterations 
in catecholamines, serotonin, GABA, and glutamate systems [15]. Hence, chronic 
stress-induced neuroadaptations in brain stress system and reward pathways may 
increase the susceptibility to self-administer the substances of abuse and predispose 
or reveal a vulnerability to psychiatric conditions, SUDs, or both [16, 17].
The influence of home and family environment is usually most important in 
childhood. Children who are exposed to parental substance use early in life are more 
likely to develop SUD in their future life through behavioral modeling [18–20]. It 
is more likely that parents or older brothers or sisters who abuse alcohol or drugs 
can increase other children’s risks of developing drug problems [21]. In addition, 
children with poor social skills and poor academic achievement may be at more risk 
of developing drug problems in school [22].
The route of administration of the substance being used is also a potential factor 
that may influence the progress of an individual from a regular user to a heavy user 
or abuse. For instance, as both smoked and injected drugs enter the brain fast and 
produce a powerful rush of pleasure, smoking a drug or taking it through the vein 
increases its addictive potential. This intense high feeling of pleasure (euphoria), 
however, can gradually fade away and a rebound effect of agitation or low feelings 
may occur. Then, these feelings develop into cravings and drive individuals to recur-
rent drug abuse to recapture the high pleasurable state which can worsen the risk of 
developing addiction [23].
The age of the onset of drug use is another potential factor that increases the 
likelihood of drug abuse by individuals. Although starting drugs at any age can even-
tually lead to addiction, early substance use is a strong indicator of problems ahead 
related to substance abuse and addiction [24]. Research findings have shown that 
people who start taking drugs at an early age are more likely to be at increased risk 
for adult substance dependence [25]. The part of the brain, the prefrontal cortex, 
which is responsible for assessing situations, making sound judgment and deci-
sions, and keeping our emotions and desires under control is still maturing during 
adolescence. The fact that this critical part of an adolescent’s brain is still a work-
in-progress puts young people at increased risk of making poor decisions regarding 
trying drugs for the first time and/or continuing drug abuse thereafter. Adolescents 
at this stage are developing judgment and decision-making skills which may limit 
their ability to assess risks accurately and make sound decisions about using drugs. 
Therefore, introducing drugs while the brain is still developing may have profound 
and long-lasting results concerning drug addiction. Early use of psychoactive 
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substances changes the structure and functions of the brain which can lead to addic-
tion and other serious problems [26]. Thus, preventing early use of alcohol or other 
drugs may reduce the risk of progressing to later abuse and addiction.
Interindividual differences in addiction risk are mostly determined by genetic 
variation. The impact of genetic variation on total addiction risk has been estimated 
to be 50% in studies focusing on variability across identical and nonidentical 
siblings [27]. The largest study to date on 1.2 million people that looked at common 
genes in alcohol and nicotine use identified genes involved in dopaminergic and 
glutamatergic neurotransmission, transcription and translation, and brain develop-
ment [28]. They also revealed that a crucial genetic component of SUDs appears 
to impact a vulnerability to disorders with pathological symptoms via a general-
purpose underlying mechanism.
Besides these common genetic characteristics, genetic variants that are mainly 
unique in a particular drug have been found. The most well-known genetic variants 
are those that code for the alcohol dehydrogenase (ADH) and aldehyde dehydrogenase 
(ALDH) enzymes, which cause poor alcohol metabolism and protect against alcohol-
ism [28]. Like other complex biobehavioral disorders, addiction is a polygenic disease 
involving multiple genes and genetic networks [29, 30]. Genetic research has aided 
our understanding of addiction-related neurobiological processes. Addiction-related 
gene variations can increase the risk of drug misuse and addiction by altering neu-
rotransmitter systems, drug metabolic pathways, and brain circuitry. For example, 
genetic polymorphisms in the nicotinic acetylcholine receptor subunits expressed in 
the medial habenula are linked to development of withdrawal symptoms [31] and are 
at least partially accountable for the genetic predisposition or vulnerability to tobacco 
addiction [32, 33]. This has demonstrated that the habenula is involved not just in 
nicotine addiction, but also in the unpleasant emotional states associated with the 
long-term use of numerous drugs of abuse [29], such as alcohol [30] and opioids [34].
Epigenetic factors are a diverse set of transcriptional tuning processes that 
generate and sustain gene expression–mediated physiological outcomes in response 
to environmental inputs [13]. Plasticity is at work in the transition to compul-
sive drug use, changing the physiology of the brain to produce addictive states. 
Physiologically, the rewiring of brain reward circuitries, particularly dopamine 
neurons in the ventral tegmental area (VTA), is thought to cause vulnerability to 
relapse after periods of attempted abstinence from drugs of abuse such as cocaine 
use. The same enzyme that attaches serotonin to Histone 3 can also catalyze the 
attachment of dopamine to H3 — a process, known as dopaminylation, which may 
control drug-seeking behavior [35]. Cocaine-induced transcriptional plasticity in 
the midbrain is mediated by histone H3 glutamine 5 dopaminylation (H3Q5dop). As 
a result, long-term cocaine use alters neuronal circuits in the brain’s reward system, 
necessitating a consistent intake of the drug for the circuits to function normally. To 
make the proteins for those changes, certain genes must be turned on and off, and 
this is an epigenetic mechanism activated by dopamine acting on H3, not a change 
in DNA sequence. Epigenetic mechanisms provide a convergent regulatory frame-
work within which the plasticity required to produce an addicted state can emerge 
and then remain long after drug use has stopped [36, 37].
2. The addiction cycle
There are many theories and models of addiction. While some of the theories 
and models present their theoretical approaches at an individual level, some explain 
the addictive behavior in terms of population or group interaction and influence. 
It is also important to note that many theories of addiction are complex and have 
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evolved over time and therefore may overlap across one or more explanatory 
domains or perspectives.
The learning theory of addiction is relatively a broad category that emphasizes 
the importance of associations among cues, responses, and positive (pleasant) or 
negative (noxious) reinforcers. Among the specific models and theories under this 
category are operant learning, classical conditioning, and drug withdrawal theory 
[38, 39]. Moreover, the incentive sensitization theory of addiction also incorporates 
aspects of learning theory as it proposes that repeated exposure to drugs and drug-
associated cues capitalizes on neuroplastic changes in mesocorticolimbic circuits 
and classical conditioning to make drugs and drug paired stimuli more motivation-
ally salient [40, 41] .
The drive theories of addiction explain that addiction involves the development 
of powerful drives reinforced by homeostatic mechanisms. The drive theory is 
part of the disease model of addiction [42] and states that addiction is the result of 
pathological changes in the brain that produces overpowering urges. These changes 
that result in impairments may involve a structural or functional abnormality in 
the CNS [42]. Among the goal-focused theories of addiction are positive reward 
theories, acquired need theories, pre-existing need theories, and identity theories. 
These theories mainly explain addiction in terms of an individual’s behavior that 
satisfies one’s physiological or psychological needs, pleasure, and aspects of self-
identity [43–47].
Other theories such as cognitive control theory [48], executive dysfunction 
theory [49–51], self-regulation theory [52], self-determination theory [53, 54], 
and implementation intentions theory [55, 56], describe addiction as a failure of 
individual’s strategies, ability or skills to self-control or to counteract impulses and 
motives underlying the addictive behavior. The biological theories describe that 
addiction involves specific neural circuitry or mechanisms [57–62] and is primar-
ily a brain disease’ characterized by dysfunction of neural pathways such as those 
that subserve executive function. The Reflective Choice Theories focus on the 
individual’s decisions, preferences, and actions that are made based on reasons and 
analysis. Therefore, according to these theories, addiction is a rational choice made 
by individuals in favor of the benefits of the addictive behavior over the costs. The 
Inhibition dysfunction theories suggest that addiction is an ongoing dysregulation 
of the ability to inhibit a rewarded behavior due to impairment of impulse control-
ling mechanisms [63]. In other words, addiction involves impairment of the inhibi-
tory system of the brain regions related to features of response selection, inhibition, 
and motivation of compulsive behaviors associated with drugs. The hedonic 
homeostatic dysregulation theory also states that addiction is a cycle of escalating 
dysregulation of the brain reward systems that gradually increases and facilitates 
the act of compulsive drug use and a loss of control over drug-taking behavior, 
which are the basic concepts that underlie the addiction cycle [64].
Drug addiction is a disorder that is chronically relapsing and manifested in 
terms of compulsive behavior to seek and consume the drug, significant loss of 
ability to control and limit drug intake, and the emergence of negative and distress-
ful emotional states such as irritability, anxiety, and dysphoria. Drug addiction 
is conceptualized as a three-stage cyclic disorder that consists of impulsivity and 
compulsivity and involves neuroplastic changes in the brain reward, stress, and 
executive functions [64, 65]. Impulsivity often dominates the early stages of the 
cycle and compulsivity dominates the terminal stages. The three stages are consid-
ered to interact with each other, become more intense, and eventually lead to the 
pathological state known as addiction.
Drug addiction is an excessive drug-taking behavior in which individuals com-
pulsively seek and take drugs and lose their ability to control in limiting their drug 
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intake. One of the multiple motivational mechanisms that drive such behavior is 
the development of a negative emotional state when access to the drug is prevented 
or discontinued, which results in dysregulation of hedonic homeostasis [64]. At 
the neurobiological level, two neuroadaptive models, sensitization and counter-
adaptation, have been hypothesized to contribute to the changes in motivation for 
drug-seeking and compulsive use (hedonic homeostatic dysregulation) and the 
neurobiological mechanisms, such as the mesolimbic dopamine system, opioid pep-
tidergic systems, and brain and hormonal stress systems [64]. While sensitization 
has been conceptualized to be a shift in an incentive-salience state since it involves 
a progressive rise in the effect of a certain drug due to its frequent administration 
(21), counteradaptation hypotheses (20), on the contrary, were closely related to 
hedonic tolerance and involve the reduction of dopaminergic and serotonergic 
neurotransmission in the nucleus accumbens during drug withdrawal (22). Critical 
neurobiological sites with specific neurotransmitters and hormones have been 
identified that may regulate the hedonic dysregulation and provide the sub-
strates that convey both vulnerabilities to, and protection against drug addiction. 
Dysregulation of key neurochemical elements in both reward and stress systems, 
such as decreases in dopamine and opioid peptide functions in the ventral striatum 
and recruitment of brain stress systems known as corticotropin-releasing factor 
(CRF) in the extended amygdala is hypothesized to produce the negative emotional 
state that initiates a condition of negative reinforcement [66]. An individual who 
uses a drug impulsively starts using it compulsively when a shift has occurred from 
positive reinforcement driving the motivated behavior to negative reinforcement 
driving the motivated behavior. Impulsivity and compulsivity often coexist in the 
different stages of the addiction cycle. This occurrence reflects the role of dysregu-
lated reward and stress systems in the negative emotional states associated with the 
withdrawal/negative affect and preoccupation/anticipation stages of the addiction 
cycle that drive drug-seeking behavior [67].
The addiction cycle becomes more severe and well-established as a person 
continues substance use and as it produces dramatic changes in the functioning of 
certain brain areas that reduce the person’s ability to control his or her substance 
abuse. Three neurobiological circuits have been recognized to have empirical value 
for the study of the neurobiological changes associated with the development and 
persistence of drug addiction linked to the three-stage cycle (Figure 1). The key ele-
ments of the ventral tegmental area and ventral striatum are the focal points for the 
binge/intoxication stage and mediate the acute reinforcing effects of drugs of abuse. 
Acute withdrawal symptoms such as increased anxiety and dysphoria are associated 
with the second stage, the withdrawal/ negative affect stage, and are most likely 
the results of disruption in the function of the extended amygdala reward system 
and the recruitment of the brain stress neurocircuitry [68]. The preoccupation/
anticipation (craving) stage is a widely distributed network and involves the stress-
induced processes at the central brain stress systems in the basolateral amygdala, 
the orbitofrontal cortex–dorsal striatum, prefrontal cortex, and the hippocampus. 
The prefrontal cortex is mainly responsible for executive functions like organizing 
thoughts and activities, prioritizing tasks, managing time, and making important 
decisions, including limiting substance consumption [65].
This three-stage model of addiction is largely attributed to the extensive works of 
George Koob [69] and his colleagues and is supported by several animal and human 
research findings which provide useful means to understand the aspects and symp-
toms of addiction and design prevention, intervention, and treatment strategies 
[70]. It is worth noting that the three stages of addiction being discussed do not have 
absolute temporal distinctions that some components of addiction such as craving, 
conditioned cued craving, incentive-salience related craving, craving linked to 
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withdrawal, etc. appear at many places in the addictive process and that the impacts 
of these aspects of craving and their neural basis remain to be further elucidated.
2.1 Stage 1: binge/intoxication
In most cases, addiction is started by abusing substances that have hedonic 
properties. Many factors contribute to the transition from drug use to drug addic-
tion, including availability (route of administration), genetics [71], prior drug use 
history, stress, and life events [72] . Initial; experimentation of drug abuse may be 
the result of peer pressure due to the rewarding effects of conforming to the peer 
Figure 1. 
A diagram depicting the spiralling distress – addiction cycle from social psychological and neurobiological 
viewpoints. NB. Stage 1: The reward circuit is overstimulated, resulting in a lack of control and bingeing.  
(A) Basal Ganglia refers to interconnected regions that are linked to learning, reward, and habit formation. 
(B) Nucleus accumbens (NAs) receives dopamine from Ventral Tegmental area, helps to control desire, 
satiation, and inhibition. (C) Thalamus is a centre that transmits sensory information and regulates arousal. 
(D) Ventral tegmental area: Dopamine is generated in this major structure near the top of the brain stem. 
Stage 2: After long-term exposure to addictive substances, the number of dopamine receptors in the nucleus 
accumbens decreases (B), requiring more of the addictive substance or action to feel the same. (B) The nucleus 
accumbens (NAs) is heavily implicated in the first and second stages of the addiction cycle. (E) The amygdala 
is linked to memory and emotions, particularly anxiety and dread. Stage 3: People who are addicted have a 
compulsive need to engage in the addictive behaviour again. The frontal cortex is thought to be affected by drug 
abuse. (F) The frontal cortex is in charge of ideas and actions. The orbitofrontal cortex is hypothesised to be 
involved in behaviour control. (G). Hippocampus: consolidated of memory. The three-stage addiction cycle 
incorporates some of the factors of possible self-regulation failure, such as under regulation and mis regulation, 
as well as the multiple DSM-5 criteria for substance dependence. The arrows depict the possible roles of several 
neurochemical and endocrine systems in the addiction cycle. Increased functional activity of DA, dopamine, 
Opioid Peptide, and CRF, corticotropin-releasing factor, is indicated by the arrows. It’s worth mentioning that 
the addiction cycle is depicted as a circular pattern that rises in amplitude with repeated exposure, eventually 
leading to addiction as a pathological condition.
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group. In some cases, the first use of a substance may be related to its therapeutic 
properties, such as opiate analgesics for the treatment of pain or stimulants such as 
amphetamine for the treatment of attention-deficit hyperactivity disorder [73].
In humans, the majority of drug users do not develop into drug abusers or drug 
addicts [74]. Similarly, even with intravenous drug administration in limited-access 
situations, stable drug intake can be observed in animals without pronounced signs 
of dependence. The current challenge is to discover the contribution of neurobio-
logical factors to individual differences in drug addiction vulnerability [64]. It is 
broadly accepted that the key elements of the reinforcing effects of drugs of abuse 
involve their ability to activate large amounts of extracellular dopamine in limbic 
regions and the nucleus accumbens. Brain imaging studies in humans revealed that 
drug-induced increases in dopamine in the ventral striatum, where the nucleus 
accumbens is located, are significantly linked to subjective correlates of reward such 
as pleasure, high, and euphoria [27, 75].
The nucleus accumbens (NAs) and the dorsal striatum (DS) are the two 
sub-regions in the basal ganglia which are particularly important in substance 
use disorders. While the NAs is involved in motivation and the experience of 
reward the DS is responsible for forming habits and other routine behaviors [76]. 
The NAs is located strategically to collect important limbic information from 
the amygdala, frontal cortex, and hippocampus that could be transformed into 
motivated behavior (the acute reinforcing effects of drugs) through its connec-
tions with the extrapyramidal motor system [70]. It is the primary site mediating 
reward behavior and thought to directly involve in reinforcing addictive behaviors 
in response to drug use. It is hypothesized that the initial action of drug reward 
depends on dopamine release in the nucleus accumbens for cocaine, amphet-
amine, and nicotine; activation of the opioid peptide receptor in the VTA (dopa-
mine activation) and nucleus accumbens (independent of dopamine activation) 
for opiates; and activation of the GABAA systems in the nucleus accumbens and 
amygdala for alcohol [70].
The dopaminergic projection from the VTA to the nucleus accumbens is known 
as the mesolimbic dopamine system (the mesolimbic pathway) and is strongly 
associated with the dependence-producing potential of addictive substances [77]. 
Many drugs of abuse directly or indirectly exert their powerful effects on this 
pathway and contribute to the development of dependence by signaling to the brain 
that addictive substances are especially important from a motivational perspective. 
The direct activation of dopamine, serotonin, opioid peptides, and GABA systems 
in the basal forebrain facilitates the acute reinforcing effects of drugs of abuse [74]. 
There are several supporting pieces of evidence for the hypothesis that addictive 
drugs dramatically activate the mesolimbic dopamine system and the serotonin 
systems, specifically, those involving 5-hydroxytryptamine-1B (5-HT1B) receptor 
activation in the nucleus accumbens, during limited-access self-administration 
[78, 79]. Several studies have shown that most addictive drugs including cocaine, 
amphetamine, and nicotine [79], either directly or indirectly, activate neurons that 
release dopamine. They produce their rewarding effects by stimulating the nucleus 
accumbens through the activation of the brain’s dopamine and opioid signaling 
system. Brain imaging studies in humans who use alcohol, nicotine, and other sub-
stance have shown activation of dopamine and opioid neurotransmitters during use 
[80, 81]. In the same manner, the primary psychoactive component of marijuana, 
tetrahydrocannabinol (THC), targets the brain’s endogenetic cannabinoid system 
and affects the reward system by influencing the function of dopamine neurons 
and the release of dopamine in the nucleus accumbens [30, 31].
Another key component of the binge/intoxication stage involves a second 
sub-region of the basal ganglia, the dorsal striatum. This part of the brain is 
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mainly related to habit formation [82]. With repeated drug use, the release of 
dopamine, glutamate (an excitatory neurotransmitter), and activation of brain 
opioid systems trigger changes in the dorsal striatum and strengthens substance-
seeking and substance-taking habits. Studies on humans showed that the rise of 
DA level in the dorsal striatum was significantly correlated with the increase of 
craving for cocaine, [83, 84]. Likewise, pharmacological blockade of the dorso-
lateral striatum after forced abstinence resulted in the reduction of drug-seeking 
behavior in rats [85–87].
As addiction progresses compulsive drug use results and neuroadaptive changes 
in the structure and function of the brain occur. Neuroadaptations involve changes 
in the reward circuitry systems that promote compulsive drug use through sensiti-
zation and counteradaptation, by increasing a drug’s positive and negative reinforc-
ing effects, respectively [82]. Sensitization arises from repeated administration of 
addictive drugs and is mediated by the mesolimbic dopamine system [84]. It is an 
increased response to a drug effect which represents a with-in system mechanism 
of neuroadaptation [82]. Animal studies posit that direct injections of opiates 
or amphetamine into the ventral tegmental area which alter the function of the 
dopamine neurons ultimately produce sensitization to later injections of these drugs 
in the periphery [83]. However, like tolerance, sensitization may develop to a certain 
drug effect but not to another [82]. The second system that plays an important role 
in sensitization, representing a between-systems mechanism of neuroadaptation, 
is the CRF (corticotropin-releasing factor) mediated stress-response system [82]. 
The CRF is a hormone released by the hypothalamus and the amygdala in response 
to certain stressors. The CRF, in turn, stimulates the release of additional stress 
hormones into the bloodstream activating a stress response system called the hypo-
thalamic–pituitary–adrenal (HPA) axis. Exposure to a variety of stressors implicates 
the CRF mediated stress-response system which promotes sensitization to the drug 
[82]. The role of sensitization in drug dependence is mainly linked to a motivational 
state described as “wanting” which progressively increases due to repeated exposure 
to drugs of abuse [85]. As “wanting” increases across repeated exposures to alcohol 
and drugs of abuse, the likelihood of relapse following periods of abstinence may 
increase, eventually leading to compulsive drug use [82].
Drug-associated stimuli raise dopamine levels in the dorsal striatum as addiction 
grows, leading to drug craving and reinforcing the habit of drug use [82]. In the 
new DSM-5 classification, drug craving as a motivational state for drug-seeking 
behavior is finally recognized as one of the main features of substance use disorders 
[88]. Cue reactivity and cue-elicited craving are both influenced by the process of 
“Positive Reinforcement,” which involves learning to associate salient cues with 
drug-use rewards [89]. Drug craving is a complex neurocognitive emotional–moti-
vational reaction to a variety of stimuli, ranging from internal to external settings, 
and from drug-related to stressful or affective experiences.
Substance craving, or “wanting” for a drug, is a common element in clinical defi-
nitions of addiction, and it appears to play a role in the maintenance of addictive 
behaviors [90]. According to Robinson and Berridge, sensitization processes which 
arise from neuroadaptations in brain reward pathways as a result of prolonged drug 
misuse are responsible for addicted animals’ excessive “wanting” or drug-seeking 
behavior [91]. They propose that these neuroadaptations result in a rise in the moti-
vational salience of drugs so that exposure to drugs and drug-associated cues causes 
excessive “wanting” or seeking, increasing the risk of relapse [92, 93]. Furthermore, 
environmental stimuli previously associated with drug use or internal cues such 
as stress responses, negative affect, and withdrawal-related states associated with 
drug abuse can function as conditioned stimuli capable of eliciting craving on their 
own [94, 95]. External drug-related stimuli, such as persons and places associated 
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with drug use, or drug paraphernalia such as needles, drug pipes, cocaine powder, 
or beer cans, as well as in vivo drug exposure, can increase drug craving and physi-
ological reactivity [96].
In summary, in the nucleus accumbens of the basal ganglia, the “reward cir-
cuitry” along with dopamine and naturally occurring opioids play a vital role in the 
rewarding effects of alcohol and other substances. Furthermore, as the addiction 
progresses, stimuli or cues associated with that substance use can cause craving, 
substance seeking, and use. Chronic alcohol or substance use and frequent activa-
tion of the “habit circuitry” or the dorsal striatum of the basal ganglia significantly 
contributes to the compulsive substance seeking and taking that potentially lead 
to SUD. The involvement of the reward and habit neurocircuits play key roles in 
substance craving and compulsive substance seeking when addicted individuals are 
exposed to alcohol and/or other drug cues in their surroundings.
2.2 Stage 2: withdrawal/negative affect
This stage is related to a neurocircuitry pathway known as the extended amyg-
dala and its connections including the major components of the brain stress systems 
associated with the negative reinforcement [84]. This pathway is composed of 
the central amygdala (CeA), the bed nucleus of the stria terminalis (BNST), and 
the NAc shell. When DA is released, it intensively activates a number of areas that 
belong to the lateral subdivision of the extended amygdala such as the bed nucleus 
of stria terminalis, BSTM, and central amygdala) [97]. The extended amygdala also 
integrates brain arousal–stress systems with hedonic processing systems to produce 
unpleasant emotional states that promote negative reinforcement mechanisms 
linked to the development of addiction [98]. For example, hyperactivation of 
amygdala has been observed in individuals with SUDs, associated with cue-induced 
drug craving [99].
Two primary sources of reinforcement (positive and negative reinforce-
ment) have been implicated to play significant roles in this allostatic process. 
Dysregulation of specific neurochemical mechanisms in the brain reward circuits 
(opioid peptides, γ-aminobutyric acid, glutamate and dopamine) and recruitment 
of brain stress systems (CRF), which are localized in the extended amygdala, are 
the reinforcing factors that provide the negative motivational state in the process 
of addiction [16, 100]. These allostatic changes in the reward and stress systems are 
assumed to maintain hedonic stability and as such contribute to the vulnerability 
for development of dependence and relapse in addiction [101].
An important component of this stage is the within-system neuroadaptations to 
chronic drug exposure which is characterized by a reduction in the function of the 
neurotransmitter systems in the neurocircuits implicated in the acute reinforcing 
effects of a drug of abuse [102]. One popular theory is that dopamine systems are 
negatively affected during key stages of the addiction cycle, such as withdrawal, 
resulting in decreased motivation for non-drug-related stimuli and increased sensi-
tivity to the abused drug [103, 104]. In animal studies, acute drug withdrawal from 
all major drugs of abuse results in decreased activity of the mesolimbic dopamine 
system and decreased serotonergic neurotransmission in the nucleus accumbens 
[105]. Symptoms of withdrawal may occur with all addictive substances, but with 
varying intensity and duration depending on both the type of substance and the 
frequency and severity of use. Brain imaging studies have consistently revealed a 
long-lasting reduction of a particular type of dopamine receptor (the D2 recep-
tor) in substance-addicted individuals compared to their counterparts. The same 
dose of stimulant causes a smaller release of dopamine in addicted persons than in 
non-addicted persons [83]. In addition, decreases in the activity of the dopamine 
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system have also been observed during withdrawal from stimulants such as opioids, 
nicotine, and alcohol [106].
Acute withdrawal mechanisms are likely to be drug-specific and reflect changes 
in the biological targets of these drugs. For example, during the first few days of 
cocaine withdrawal, the brain becomes more sensitive to the effects of GABA-
enhancing drugs, which may reflect the down regulation of this neurotransmitter in 
chronic cocaine users [107]. Brain imaging studies have shown decreased levels of 
endogenous opioids during cocaine withdrawal, which could explain the irritability, 
tiredness, and dysphoria experienced during the motivational phase of withdrawal 
[108]. Similarly, Imaging studies have documented hypofunction in dopamine 
pathways during protracted withdrawal, as evidenced by decreases in D2 receptor 
expression and decrease in dopamine release, which may contribute to the anhe-
donia (i.e., decreased sensitivity to rewarding stimuli) and motivation reported by 
drug-addicted subjects during protract withdrawal [109]. 
Typical neurochemical changes in these structures include not only reduc-
tions in reward system functioning, a within-system opponent processes, but also 
recruitment of the brain stress systems intermediated by corticotropin-releasing 
factor (CRF) and dynorphin- k opioid systems in the ventral striatum, extended 
amygdala, and frontal cortex known as a between-system opponent processes [80]. 
A between-system neuroadaptation is the second component of the withdrawal/
negative affect stage. This process involves the activation of stress neurotransmit-
ters such as corticotropin-releasing factor (CRF), norepinephrine, and dynorphin 
in the extended amygdala [85]. Regardless of the presence of the drug, the neu-
rochemical systems involved in stress modulation may be triggered within the 
neurocircuitry of the brain’s stress systems to overcome the persistent effects of 
the distressing substance and restore normal function [110]. These neurotransmit-
ters play a role in the development of negative feelings associated with withdrawal 
which leads to stress-triggered substance use. Chronic khat chewers attempting to 
quit chewing, for example, exhibited withdrawal symptoms that followed similar 
overall patterns, with notable elevations after the quit day. Most of the khat users 
relapsed within 11 days and very few maintained abstinences [111]. Negative affects 
including depression, nervousness, tiredness, restlessness, poor motivation, irrita-
bility, as well as craving substantially increased and reached their peak on the first 
week of khat cessation and remained higher there after indicating the persistence 
and severity of these symptoms over time [112].
The aforementioned phenomena have been well demonstrated both in animal 
and human studies [113]. Administration of antagonists for neurotransmitters sig-
nificantly reduced substance intake in response to withdrawal and stress. Similarly 
stopping the activation of stress receptors in the brain lowered alcohol consumption 
in both alcohol-dependent rats and humans with alcohol use disorder [86, 87]. 
Hence, the desire to remove the negative feelings associated with withdrawal can be 
a strong driving force to continuous consumption of the substance since the taking 
of the substance at least momentarily relieves the negative feelings caused by the 
withdrawal. This process is, however, a vicious cycle as taking substances to reduce 
withdrawal symptoms during the period of abstinence makes it even more difficult 
to maintain abstaining the next time a person tries to quit the drug of abuse [56].
In summary, this stage of addiction involves a reduction in the function of the 
brain reward systems involving dopamine receptors and the activation of brain 
stress hormones and neuropeptide (CRF, dynorphin, and norepinephrine) in the 
extended amygdala. The combination of these events significantly contributes 
to providing a powerful neurochemical basis that produces a negative emotional 
state associated with drug abstinence or withdrawal. Increases in drug desire 
and physiological reactivity have also been linked to negative affect, stress, or 
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withdrawal-related suffering [114–117]. The strong desire to relieve these adverse 
feelings, in turn, drives additional sources of negative reinforcement in compulsive 
substance taking or drug addiction.
2.3 Stage 3: preoccupation/anticipation
The preoccupation/anticipation (craving) stage mainly involves the Prefrontal 
Cortex, the region that controls executive functions like organizing thoughts and 
activities, task prioritization, time management, decision making, and regulation of 
one’s actions, emotions, and impulses. Executive function is necessary for a person to 
make suitable choices about whether or not to submit to strong urges that may com-
pel individuals to use substances, specifically, when the person encounters triggers 
and cues such as stimuli associated with that substance or stressful circumstances.
The preoccupation/anticipation stage, which is characterized by an increase in 
drug craving, is triggered by increased sensitivity to conditioned cues. An indi-
vidual is driven to seek drugs of abuse again after a period of abstinence. Stress 
promotes relapse to drug-taking behaviors by activating brain circuits involved in 
reward processing as well as attentional and memory preferences for drug use cues 
[17, 118]. Chronic relapse is widely acknowledged as the most challenging obstacle 
in the fight against drug addiction. Long after encountering acute withdrawal 
symptoms, users are likely to return to compulsive drug use [119]. Chronic drug 
misuse is believed to cause a gradual restructuring of reward and memory circuits, 
which is thought to be critical to the mounting of these reactions. In clinical studies, 
both dopamine and glutamate have been identified as contributing to the neural 
alterations associated with conditioned responses [120].
The Incentive-Sensitization Theory of Addiction explains that drug-induced 
sensitization in the brain’s mesocorticolimbic circuits, which assign incentive 
salience to reward-associated events, is the primary cause of addiction [41]. 
Incentive salience or “wanting,” is generated by neural systems that comprise 
the mesolimbic dopamine. The role of this neural system is to attribute incentive 
salience or motivational importance to stimuli resulting their being viewed as 
highly salient, attractive, and “wanted” [40, 121]. Addictive drug administration, 
both continuous and occasional, causes incremental neuroadaptations in this 
neuronal system. Associative control of this sensitized neural system causes sig-
nificantly increased incentive salience to be ascribed to the act of drug taking and 
stimuli related to drug-taking. This process is believed to occur due to hyperactiva-
tion of the dopamine system resulting in drugs and drug associated cues becoming 
pathologically more “wanted” by the drug user. Irrespective of other motivating 
variables such as the expectation of drug pleasure or the unpleasant aspects of 
withdrawal, sensitization of the neural system responsible for incentive salience can 
motivate addictive behavior such as compulsive drug seeking and drug-taking. The 
concomitant targeting of sensitized incentive salience to drug-related cues results 
in the recurrence of addictive behavior in the face of multiple barriers, including 
the loss of one’s reputation, job, home, and family. This shows that drug addiction is 
motivated by a strong desire for drugs, often labeled as drug craving [122].
The Incentive-Sensitization Theory of Addiction offers a novel neuropsycho-
logical explanation for drug addiction. Due to dopamine system sensitization, 
drug craving is the subjective sensation that comes with the attribution of exces-
sive amounts of incentive salience to drug-related stimuli or their mental images. 
This system causes pathological incentive motivation “wanting” for drugs that 
differ from both the unpleasant symptoms of withdrawal and drug pleasure. 
Although exposure to drug-related stimuli increased self-reported craving, as well 
as drug-opposite and drug-like effects, the cumulative effects of positive outcome 
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expectancies, cue-specific dysphoria, and cue-specific drug-positive reactions were 
able to predict 28 percent of the variance in cue-specific craving in a simple additive 
model [40, 123].
The changes that are taking place in the brain’s reward and emotional circuits 
are followed by changes in the function of the cortical prefrontal cortex involved in 
the executive processes. Down-regulation of dopamine signals, which obscures the 
sensitivity of the reward circuits to pleasure, also occurs in the pre-frontal cortex and 
linked circuits, seriously affecting executive processes including the self-regulation, 
decision-making, flexibility in action selection, and initiation or assignment of salience 
(assignment of relativity) [124]. Neuroplastic changes in glutamatergic signals further 
disrupt the modulation of the reward and emotional circuits of the prefrontal regions. 
In people with drug addiction, the impaired signaling of dopamine and glutamate in 
prefrontal brain regions diminishes their ability to withstand strong urges or take strong 
decisions to stop taking the drug of abuse. These effects explain why people with addic-
tion can be sincere in their desire and intention to stop using a substance while being 
impulsive and unable to follow through on their determination. Thus, changed signaling 
in prefrontal regulatory circuits, along with changes in rewards and emotional response 
circuits, causes an imbalance which is responsible for both progressive development of 
compulsive behavior in addictive diseases state and the related failure of individuals with 
addiction to voluntarily reduce the behavior [125].
Some scientists separate the functions of the prefrontal cortex into two opposing 
systems to better understand how this brain region is engaged in addiction: a “Go 
system” and a “Stop system” [80]. The Go system assists people in making decisions 
on topics that need a lot of thought and planning, as well as engaging in behaviors 
that are necessary for achieving life goals. When substance-seeking behavior is 
triggered by substance-related environmental cues (incentive salience), the Go 
circuits of the prefrontal cortex show significant increases in activity. As a result, 
the nucleus accumbens is stimulated to release glutamate, the brain’s principal 
excitatory neurotransmitter [126]. In addition, the neurons in the Go circuits of 
the prefrontal cortex stimulate the habit systems of the dorsal striatum through 
connections that use glutamate and contribute to the impulsivity associated with 
substance-seeking behavior of a person [127].
Conversely, the Stop system primarily hinders the activity of the Go system 
[126]. The nucleus accumbens and habit responses driven by the dorsal striatum, 
that are areas of the basal ganglia implicated in the binge/intoxication stage of 
addiction, are controlled by Stop system. This system, according to researchers, 
helps to reduce incentive salience, or the ability of substance-related stimuli to 
trigger a relapse. The Stop system also plays an important role in relapse triggered 
by stressful life events or circumstances by exerting control on the brain’s stress 
and emotional systems [126]. As explained above, the brain’s stress and emotional 
systems involve the activation of stress hormones and neurotransmitters (CRF, 
dynorphin, and norepinephrine) in the extended amygdala caused by prolonged 
abstinence during the withdrawal/negative affect stage of addiction [109].
Imaging studies using laboratory animals revealed that lower activity in the Stop 
system of the prefrontal cortex is associated with increased activity of stress cir-
cuitry involving the extended amygdala, which increased substance-taking behav-
ior and relapse [109]. Similar studies in humans with addiction show dysfunction of 
both the Go and Stop circuits [65, 109]. For example, people with alcohol, cocaine, 
or opioid use disorders exhibit significant deficiencies in executive functions such 
as impairments in the maintenance of spatial information, disruption of decision-
making and behavioral inhibition. These executive function deficits are equivalent 
to the changes in the prefrontal cortex which suggest decreased activity in the Stop 
system and greater reactivity of the Go system in response to substance-related 
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stimuli. Moreover, research findings suggest that humans with post-traumatic stress 
disorder (PTSD), a syndrome that is usually accompanied by drug and alcohol use 
problems, have decreased prefrontal cortex control over the extended amygdala 
[75]. These findings add to the growing body of evidence supporting the impor-
tance of the prefrontal cortex-extended amygdala circuit in stress-induced relapse 
and imply that strengthening prefrontal cortex circuits may be crucial for the inter-
vention and treatment of substance use disorders. The preoccupation/anticipation 
stage of the addiction cycle is characterized by a disruption of executive function 
caused by a compromised prefrontal cortex [128]. It is a key element of relapse in 
humans and the basis for defining addiction as a chronic relapsing disorder. While 
the over-activation of the Go system in the prefrontal cortex is related to habit-like 
substance seeking, the under-activation of the Stop system in the prefrontal cortex 
stimulates impulsive and compulsive substance seeking.
Overall, the study of neurobiological changes has identified three neurobiological 
circuits with heuristic value concerning the development and persistence of SUD. The 
three stages which involve different brain regions, neuro-circuits, and neurochemi-
cals are interrelated to bring about specific kinds of changes in the brain. Activities in 
the nucleus accumbens-amygdala reward system, ventral tegmental dopamine input, 
and local opioid peptide and GABAergic circuits are among the acute reinforcing 
of drugs involved in the binge/intoxication stage addiction cycle. In contrast, acute 
withdrawal symptoms that are critical for addiction, such as dysphoria and height-
ened anxiety, are thought to be caused by reduced function of the extended amygdala 
reward system and activation of brain stress neurocircuitry during the withdrawal/ 
negative affect stage [78]. The preoccupation/anticipation (or craving) stage of 
addiction is characterized by the considerable increase of activities in the Go systems 
of the prefrontal cortex as incentive salience initiates substance seeking behavior. 
This results in major afferent projections to the nucleus accumbens and extended 
amygdala, in particular, the prefrontal cortex (for drug-induced reinstatement) and 
basolateral amygdala (for cue-induced reinstatement). Increased activities in this 
circuit further boost incentive salience and produces strong desire to use the sub-
stance in the presence of drug-related stimuli. The dorsal striatum’s habit-response 
mechanisms are also activated by the Go system, which contributes to the impulsivity 
associated with substance seeking [126]. It’s considered that the shift from ventral 
striatal-ventral pallidal-thalamic-cortical loops to dorsal striatal-pallidal-thalamic-
cortical loops is implicated in compulsive drug-seeking behaviour [129].
Molecular neuroadaptations start with the stage of binge/intoxication and as 
substance abuse progresses, transitions through the addiction cycle may bring about 
changes in long-term transcription which may convey a risk of relapse. A person may 
go through this cycle for weeks or months or progress through it several times in a day 
due to several factors including the type, amount, and frequency of substances used. 
There may also be a difference in how a person progresses through the cycle and the 
intensity with which he/she experiences each of the stages. In addition to this, it is to 
be noted that there are not absolute functional nor temporal boundaries that can be 
drawn between the stages in the process of addiction and therefore as the withdrawal/
negative affect aspects of addiction develop those effects from stage 1 persist (though 
reward may be attenuated) and those in stage 3 begin to emerge. Moreover, deficits in 
executive function are potential risk factors for developing addiction.
3. DSM-5 substance use disorder
Drug abuse, substance-related problems, and substance use disorders (SUDs) 
have all been viewed in different ways throughout history and cultures. How drug 
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use and SUDs are conceptualized and how symptoms manifest and are interpreted 
are all influenced by culture. Sociocultural beliefs can influence how people 
approach and behave when it comes to substance use and misuse. Individuals’ 
assumptions regarding potential drug-related problems are shaped in large part by 
their culture [130]. While in some cultures alcohol use was heavily controlled and 
was allowed only for ceremonial purposes [131], acculturation, on the other hand, 
has made significant contribution to accelerated abuse of alcohol and use of illegal 
drugs among certain groups of people [132, 133].
Although the characterization of substance problem syndromes as medical 
diseases or disorders has a long history, drug abuse and inebriety were historically 
regarded from a moralistic perspective [134]. Attempts to define and refine diag-
nostic criteria for SUDs began in the mid-twentieth century and are still ongoing. 
Research has identified some limitations in the existing diagnostic criteria for SUDs, 
which can help with the conception of future classification systems [135].
According to modern theories of substance dependence, chronic substance 
use can cause neuroadaptations in brain systems involved in reward, motivation, 
emotional regulation, inhibitory control, and tolerance/withdrawal, all of which 
can lead to compulsive drug use behavior [136]. Illicit drug usage has been docu-
mented all over the world with the highest estimates in Europe, North America, and 
Australasia. Regular use, “problem drug use,” and drug addiction are less commonly 
measured, although they are critical to quantify in order to determine disease burden 
and risk factors for illicit drug use [137]. To better understand the harms associ-
ated with illicit drug dependency, future research should focus on collecting better 
estimates of mortality and morbidity.
Substance use and SUDs follow standard epidemiological age-related trends, 
with an onset often in late adolescence or early adulthood, showing peak prevalence 
in emerging adulthood, and then a decline. Although substance abuse is less com-
mon among older persons, often has a greater impact when it does occur, making it 
a public health concern [137]. A careful review of the population-based empirical 
literature reveals the importance of considering substance use in the context of 
development, with specific developmental aspects linked to the origin, course, and 
resolution of the problem.
SUDs are defined and thought of in a variety of ways. They have a lot in com-
mon with other chronic, recurrent diseases like diabetes or high blood pressure 
from a public health standpoint. Chronic diseases with significant behavioral 
health components may necessitate a lifelong commitment to manage and 
control. Many professionals believe that SUDs are inherently progressive. To put 
it another way, if these diseases are not treated, they tend to worsen over time. 
This chronic disease viewpoint has sparked significant controversy. For exam-
ple, there is abundant evidence that many people, especially those suffering 
from the most severe kinds of addiction, follow a chronic, relapsing, escalating 
cycle. However, many people with SUDs seem to “recover” without undergoing 
professional therapy. This pattern, however, does not apply to everyone who has 
been diagnosed with a SUD. Many persons with milder, earlier-stage SUDs do 
not relapse and their substance-related problems do not progress [138]. Some 
experts, on the other hand, contend that, despite their history of chronic sub-
stance abuse, these individuals may not have been suffering from a severe SUD. 
Because of the great degree of individual variability in the course of addiction, it 
appears imprudent to employ a single treatment approach for all people diag-
nosed with the illness [138]. Despite age-related norms, significant individual 
course variability seems to be observed and contemporary statistical approaches 
have found numerous unique prototypic courses that appear to differ in their 
factors and outcomes. Research on substance use and misuse from a lifetime 
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perspective has significant implications for the design and implementation of 
successful, developmentally informed diagnosis, prevention, and intervention 
programs [136].
The Diagnostic and Statistical Manual of Mental Disorders (DSM) is a clas-
sification manual for mental illnesses. It establishes a classification system for 
clinicians, insurance providers, researchers, and policymakers to utilize during 
diagnosing, researching, and treating mental illness. The 4th edition (DSM-IV) of 
the DSM, which had been in use for almost a decade, was replaced in 2013 by the 
5th edition (DSM-5) [134, 135]. This version included organizational modifications 
as well as significant revisions to the diagnostic criteria for nearly every DSM-IV 
disorder. Some SUDs had just minor wording modifications, while others had sig-
nificant criterion revisions. Some disorders have been added to and some removed 
from the list [136].
The transition from DSM-IV to DSM-5 has relevance in a multitude of settings, 
and it is essential for diagnosing and treating mental illness and SUD, as well as 
medical billing procedures and mental health research. Furthermore, if the modi-
fications result in significant changes in the estimate of illness burden in the United 
States, they may be relevant to policymaking [136]. Every year, the National Survey 
on Drug Use and Health (NSDUH) gathers data on substance abuse and mental 
health from roughly 70,000 occupants of households and noninstitutional group 
quarters (e.g., shelters, rooming houses, and dormitories) as well as civilians resid-
ing on military bases. The NSDUH data give current, relevant information on the 
nation’s substance use and mental health status to the drug use and mental health 
prevention, treatment, and research communities. Stakeholders and policymakers 
can utilize this data to learn more about the disease burden, temporal patterns, and 
repercussions of substance abuse and mental illness, as well as identify high-risk 
groups [136]. Professionals in the United States currently rely extensively on the 
diagnostic method outlined in the DSM-5 for diagnosing substance use disorders 
[136]. Many nations throughout the world use the 11th edition World Health 
Organization’s (WHO, 2016) International Statistical Categorization of Diseases 
and Related Health Problems version 10, (ICD-10).
According to the DSM-5, SUDs are a type of a class of disorder (substance-
related disorders) that are “associated to the use of a drug of abuse (including 
alcohol)”. Although there are changes at various levels in the shift from DSM-IV 
to DSM-5 for SUDs, the core criteria stay the same [134, 135, 139]. However, there 
have been changes at the category/class level (see Table 1 for the specific disor-
ders considered within the overall group of disorders), substance level (which 
substances are considered “drugs of abuse”), disorder level (the template of 
criteria that is applied, with some deviations, across all substances), and indi-
vidual criteria level (the number and types of symptoms needed to meet criteria 
for a disorder) [140]. Changes in relation to categorization refer to a disorder’s 
“class,” which is used in the DSM to designate groups of related disorders (e.g., 
personality disorders and anxiety disorders). The DSM-5 includes several revi-
sions to the classification system, one of which is the classification of SUDs. SUDs 
were classified as substance-related disorders in the DSM-IV, which contained 
solely substance/drug-based illnesses. Gambling disorder has been added to this 
classification in DSM-5, and the section has been renamed Substance-Related 
and Addictive Disorders [136]. Changes from DSM-IV to DSM-5 in the types of 
substances assessed have been minor, but some reclassification has occurred. 
Based on empirical evidence since they have similar mechanisms of action (boost-
ing synaptic dopamine), symptom profiles, consequences, and prognoses, cocaine 
(including crack) and amphetamines have been merged with other stimulants 
(except caffeine) into a distinct stimulant class [140].
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The merging of substance abuse disorder and substance dependency disorder 
into a single SUD is a fundamental alteration in the criteria for substance use 
disorders from DSM-IV to DSM-5. DSM-5 has combined what had previously 
been considered as two distinct and hierarchical disorders (substance abuse 
and substance dependence) into a single construct, SUD, classifying it as mild, 
moderate, or severe, with the severity of an addiction based on how many of the 
established criteria are met. Diagnosis of SUD requires two out of eleven criteria 
to be met in a 12-month period. In addition, the DSM-5 has included a craving 
criterion to replace the abuse criterion associated with recurring substance-related 
legal difficulties (e.g., arrests for substance-related disorderly conduct). Due to 
low endorsement, poor fit with other items, and poor discrimination of this item 
(nearly everyone endorsing the legal criteria also endorsed other criteria), the 
Characteristic DSM-IV DSM-5
Disorder Class Substance-related disorders, included only 
SUDs
Substance-related and addictive 
disorders now include SUDs and 




Because of the hierarchical diagnostic guidelines 
for abuse and dependence, people who met the 
criteria for dependence were never diagnosed 
with abuse for the same class of substance.
SUD, substance abuse, and 
dependence have all been replaced 
with one diagnosis, SUD.
Substances 
Assessed
11 classes of substances assessed, plus 2 
additional categories
10 classes of substances assessed, 
plus 2 additional categories
Alcohol Alcohol
Amphetamine and similar sympathomimetics Stimulant use disorder, which 
includes amphetamines, cocaine, 
and other stimulants
Caffeine (intoxication only) Caffeine (intoxication and 
withdrawal)
Cannabis (no withdrawal syndrome) Cannabis (with withdrawal 
syndrome)
Cocaine Combined with other stimulants 
(e.g., amphetamines) under 
stimulant use disorder
Hallucinogens Phencyclidine and similar 
arylcyclohexylamines
Separated into phencyclidine use 
disorder and other hallucinogen use 
disorder
Inhalants (no withdrawal syndrome) Inhalants (no withdrawal 
syndrome)
Nicotine (dependence only) Tobacco
Opioids Opioids
Merged with hallucinogens
Sedatives, hypnotics, and anxiolytics Sedatives, hypnotics, and 
anxiolytics
Other drug abuse/dependence Any other SUD
Polysubstance dependence Dropped polysubstance use 
disorder
Table 1. 
Comparison of DSM-IV and DSM-5 Substance Use Disorder Assessment.
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legal problems criterion was omitted (see Table 2) [136, 141]. The majority of 
cases that met DSM-IV abuse criteria will not receive a DSM-5 diagnosis since they 
do not meet the minimum two-criterion threshold for a mild SUD. Most DSM-IV 
abuse cases will now be classified as mild SUD if they also endorsed two depen-
dence criteria, but those who endorsed multiple (i.e., two or three) abuse criteria 
and two to three dependence criteria will now be classified as moderate SUD [137]. 
DSM-IV dependence cases that met three dependence criteria and no more than 
two abuse criteria will be classified as moderate SUDs in DSM-5, whereas nearly 
all cases that met four or more dependence criteria will be classified as severe 
SUDs [140]. The withdrawal dependence criterion is another criterion that has 
undergone some changes in DSM-5. Unlike other criteria, withdrawal symptoms 
are unique to the substance’s physiological action (see Table 2). Withdrawal is 
manifested by (1) a person experiencing the substance’s characteristic withdrawal 
symptoms, or (2) a person taking the same or a closely comparable substance 
to avoid the substance’s unique withdrawal symptoms in both DSM-IV and 
DSM-5. Except for cannabis, the DSM-IV and DSM-5 withdrawal criteria remain 
intact [136].
For that category of substances, the DSM-IV requires the endorsement of one or 
more symptoms (out of four, at any time) and no history of substance dependency 
(see Table 2 for the specific criteria) [136]. In addition, in order to meet the substance 
dependence criteria, three or more symptoms (out of seven) have to be confirmed in 
12-month period. According to DSM-IV diagnostic hierarchy standards, people who 
met both substance abuse and substance dependence criteria for a particular sub-
stance were labeled as having substance dependence alone. The objective of this was 
to highlight the severity of dependence as compared to the abuse diagnosis [136].
The separate abuse and dependence disorders have been eliminated from DSM-5 
for several reasons: (1) the separation has little guidance for treatment; (2) the 
separation created “diagnostic orphans” (those who endorsed two dependence 
symptoms but no abuse symptoms and hence did not meet any diagnostic criteria); 
(3) the hierarchical structure did not follow the expected relationship between 
abuse and dependence (that abuse was largely a less severe symptom of depen-
dence); and (4) the division caused the abuse diagnosis to suffer from substantial 
reliability problems [136, 140, 142, 143].
A cluster of symptoms related to cannabis withdrawal has been uncovered in 
research undertaken following the release of the DSM-IV, and this new informa-
tion has been included in the DSM-5 [2]. The presence of three or more symptoms 
occurring within one week of stopping severe and persistent cannabis use is 
known as cannabis withdrawal syndrome. (1) irritability, anger, or depression; (2) 
nervousness or anxiety; (3) sleep problems (e.g., insomnia or unpleasant/vivid 
dreams); (4) decreased appetite or weight loss; (5) restlessness; (6) depressed 
mood; and (7) at least one physical symptom that causes considerable discomfort 
such as abdominal pain, shakiness/tremors, sweating, fever, chills, or headache, are 
all possible symptoms [136].
The severity Criteria were another significant change between the two versions 
of diagnostic criteria. The DSM-IV did not directly measure the severity of SUDs, 
though dependence was generally thought to be more severe than abuse, and 
patients who were diagnosed with dependence did not obtain an abuse diagnosis 
even if the criteria for abuse were met [136]. A symptom count-based severity indi-
cator has been added to DSM-5, with two to three symptoms classified as mild, four 
to five symptoms categorized as moderate, and six or more symptoms categorized 
as severe. A study found that a simple symptom count was as successful at evaluat-

































Disorders Assessed Substance abuse: SUD: Two out of 11 criteria clustering in a 12-month period
One or more symptoms Recurrent substance-related legal problems Dropped
The substance is used in larger amounts or for a longer period of time than was intended 
(1).
Same
There is a persistent desire or unsuccessful efforts to cut down or control substance use (2). Same
A great deal of time is spent in activities necessary to obtain the substance, use the 
substance, or recover from its effects (3)
Same
Craving (4): no craving Added
Three or more 
symptoms in the same 
12-month period 
(or one symptom if 
dependence criteria 
have been met 
previously in the 
lifetime
Substance dependence:
Recurrent substance use resulting in a failure to fulfill major role obligations at work, 
school, or home (5)
Same
Continued substance use despite continuous or recurring social or interpersonal issues 
created or aggravated by the substance’s effects (6).
Same
Important social, occupational, or recreational activities are given up or reduced because of 
substance use (7)
Same
Recurrent substance use in situations where it is physically hazardous (8) Same
Substance use is continued despite knowledge of having a persistent or recurrent physical 
















Tolerance, as defined by either: (1) a need for markedly increased amounts of substance to 
achieve intoxication or desired effect or (2) a markedly diminished effect with continued 
use of the same amount of the substance (10)
Same
Withdrawal, as manifested by either: (1) the characteristic withdrawal syndrome for 
the substance (excludes Cannabis, Hallucinogens, and Inhalants) (2) the substance (or a 
similar substance) is taken to relieve or avoid withdrawal symptoms (11).
Withdrawal, as manifested by either: (1) withdrawal syndrome 
characteristic for the substance (excludes Phencyclidine, Other 
Hallucinogens, and Inhalants) (2) the substance (or a closely related 
substance) is taken to relieve or avoid withdrawal symptoms (Except 
for those taking opioids, sedatives, hypnotics or anxiolytics, or 
stimulant medications solely under appropriate medical supervision).
Severity No severity criteria Severity is determined by the number of symptoms Mild: 2 to 3 
symptoms. Moderate: 4 to 5 symptoms. Severe: 6 or more symptoms.
Additional 
Specifications
With or without physiological dependence, early full remission, early partial remission, 
sustained full remission, sustained partial remission, on agonist therapy, and in a 
controlled environment
Early or sustained remission and if the person is in a controlled 
environment where access to the substance is restricted
Table 2. 
Comparison of DSM-IV and DSM-5 Substance Use Disorder Criteria.
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3.1 Criteria for diagnosing substance use disorders
Drug addiction is a progressive and chronically relapsing disorder that develops 
from infrequent, limited, and regulated use of a substance to compulsive usage 
[145]. When people are unable to obtain the substance to which they are addicted, 
they suffer from unpleasant emotional states (dysphoria, anxiety, irritability, 
and other negative feelings) due to low level of reward, excessive stress, and 
compromised executive function. Eventually, the individual returns to excessive 
drug-seeking and excessive drug taking behavior. This, in turn, activates CRF in the 
medial PFC accompanied by executive function deficits that may aid the transition 
to compulsive like behavior [146].
The addiction process is cyclic and consists of three stages which are intercon-
nected and can lead to a recurrent sequence of addictive behaviors characterized by 
increasing and persistent levels of psychological and physical problems over time 
[145]. Each of the components of the cycle involves a distinct psychosocial and 
behavioral manifestation relevant to the DSM-5 diagnostic criteria (see Figure 1).
The changes in various components of reward neurocircuitry may represent the 
different social psychological and behavioral components involved in the addiction 
cycle. The social-psychological components of lack of strength and self-regulation 
with regard to controlling substance use, for example, may reflect increased activity 
in the stress system and be linked to individuals’ failures despite their persistent 
desire to limit or quit using addictive substances and using them in larger quantities 
than intended (refer to Figure 1). This process signifies the preoccupation/anticipa-
tion stage which eventually leads to a cycle of binge use and relapse [68]. In this 
stage, increased dopaminergic and opioidergic neurotransmission may be involved, 
resulting in sensitization. On the other hand, monitoring or attentional failures are 
linked to people’s preoccupation with getting drugs, and they may reflect cogni-
tive alterations impacted by broadly distributed brain monoamine systems. In this 
situation, counteradaptation is caused by compromised dopamine, serotonin, and 
opioidergic neurotransmission, as well as increased stress neurotransmitters, which 
may be responsible for the negative emotional state developed due to withdrawal. 
The combination of a change in the hedonic set-point caused by repeated counter-
adaptation and a different mechanism for sensitization would provide a powerful 
motivational drive for drug addiction to persist [68].
The DSM-5 states that a person must fulfill certain criteria to be diagnosed with 
a substance use disorder. Currently, there are 11 criteria (see Table 2) used to make 
such a diagnosis which can be divided into four categories [141].
a. Impaired control: Impaired control can manifest itself in a variety of ways:
 (1) Using a substance for longer than the intended time or in higher amounts 
than intended; (2) Wanting to cut down on usage yet failing to do so; (3) 
Excessive time spent obtaining, using, and recovering from drug use; (4) 
Cravings that are so strong that thinking about anything else is difficult.
b. Social impairment (5) Substance use negatively affects the ability to ful-
fill responsibilities at home, workplace, and school. People may continue 
to use despite recurring and worsening social problems or problems with 
work, school, or family/social obligations. This might include repeated work 
absences, poor school performance, neglect of children, or failure to meet 
household responsibilities. (6) Addiction may also be suggested if a person 
continues to use substances while having interpersonal problems due to 
substance use. Interpersonal problems may include arguments with family 
members concerning substance use, as well as the loss of vital friendships as a 
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result of prolonged substance use. (7) Giving up Important social, work, and 
recreational activities for the sake of substance use. Substance abuse may cause 
important and meaningful social and leisure activities to be abandoned or 
curtailed. A person may spend less time with his or her family or quit outdoor 
plays with his or her friends.
c. Risky Use: The central issue of this criterion is the failure to quit using the 
substance despite the harm it causes.
(8) Addiction may be indicated when someone takes substances in physically 
unsafe or dangerous conditions regularly. For instance, using alcohol or other 
drugs while operating machinery or driving a car. (9) Some people continue to use 
addictive substances even if they are aware that addictive substances are creating 
or exacerbating bodily and psychological problems. An individual may continue to 
smoke cigarettes despite having a respiratory condition such as asthma or chronic 
obstructive pulmonary disease (COPD), such as chronic bronchitis.
d. Pharmacological indicators: Tolerance and Withdrawal
This criterion describes how the body adjusts or attempts to maintain homeo-
static equilibrium to the sustained and frequent usage of a substance. For most 
people, tolerance and withdrawal are hallmark markers of progressing addiction. 
(10) Tolerance develops when people require a higher dose of a substance to obtain 
the same effect. To put it another way, it’s when someone gets less of a result with the 
same amount of effort. Either the desire to avoid withdrawal symptoms or to become 
high could be the “desired effect.” Tolerance is experienced differently by different 
people, i.e., people’s sensitivities to different drugs differ. The rate at which tolerance 
develops and the dose required for tolerance to develop will differ depending on the 
substance [88]. (11) Withdrawal is the body’s reaction to abrupt discontinuation of 
a drug once the body has built a tolerance to it. Each drug produces a distinct set of 
(sometimes unpleasant and lethal) symptoms (refer to the previous section for the 
unique symptoms in each category of substance). Although withdrawal is painful, 
it usually does not necessitate medical intervention. However, withdrawing from 
certain drugs, on the other hand, can be so deadly that medical advice may be critical 
before trying to quit them after a long period of use [88].
While an individual must meet at least two of the above criteria to be diagnosed 
with a SUD, the severity of the addiction is decided by the number of criteria met. 
A mild SUD might be the diagnosis, if two or three of these symptoms are present. 
A moderate SUD would be a more appropriate diagnosis if a person exhibits four or 
five of these symptoms. Ultimately, a severe SUD occurs when a person exhibits six 
or more of these symptoms. Substance withdrawal, however, is a distinct diagnosis 
that may or may not be associated with a substance use disorder diagnosis [88].
4. Conclusion
Addiction is caused by the brain’s gradual adaptation of neuronal activity to 
long-term drug exposure, which results in fundamental neuroplastic changes. The 
extended amygdala (EAc) is a network made up of the central amygdala and the 
stria terminalis’ bed nucleus. This important location is in charge of controlling 
drug cravings and seeking behaviors [147]. Drug addiction signifies a three-stage 
intense dysregulation of motivational circuits due to a combination of excessive 
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incentive salience and habit formation [148], reward deficits and excessive stress, 
and impaired executive function [64, 80, 126].
Changes in dopamine and opioid peptides in the basal ganglia are involved in the 
rewarding effects of drugs of abuse, the development of incentive salience, and the 
development of drug-seeking habits in the binge/intoxication stage. In the with-
drawal/negative affect stage, decreases in the function of the dopamine component 
of the reward system, as well as recruitment of brain stress neurotransmitters like 
corticotropin-releasing factor and dynorphin in the neurocircuitry of the extended 
amygdala, lead to an increase in negative emotional states and dysphoric and stress-
like responses. The dysregulation of critical afferent projections from the prefrontal 
cortex and insula, particularly glutamate, to the basal ganglia and extended 
amygdala, causes craving and executive function deficiencies in the preoccupation/
anticipation stage [68].
Almost all addictive substances have the common property of increasing 
mesolimbic dopamine function. The mesolimbic dopamine (DA) pathway by which 
the DA cells in the ventral tegmental area (VTA) projecting into the nucleus accum-
bens (NAc) seems to be crucial for drug rewards. Most psychostimulants such as 
cocaine [149] amphetamine [150] narcotic analgesics [151], nicotine [152], alcohol 
[153], and phencyclidine [150] stimulate dopamine transmission in the nucleus 
accumbens [151], the main area of the ventral striatum. A couple of other dopamine 
pathways the mesostriatal (DA cells in substantia nigra [154] projecting into dorsal 
striatum) and the mesocortical (DA cells in VTA projecting into frontal cortex) 
are recently recognized to have a contribution to drug reward and addiction. 
Alcohol and other substances of abuse are fundamentally rewarding in that they 
are consumed by humans or self-administered by laboratory animals. As a result, 
individuals exposed to drugs, though small in percentage, will become addicted and 
move from controlled drug use to compulsive and uncontrolled drug consumption 
despite adverse consequences.
The three stages involving the different neurochemicals and regions of the brain 
are integrated and feed each other producing strong drives for substance seeking. 
The addiction cycle tends to intensify over time and progress to greater physical 
and psychological harms. People with such disorders may have distorted thinking 
and abnormal behaviors as a result of changes in the brain’s structure and functions. 
Brain imaging studies on people who frequently use psychoactive substances show 
marked changes in the areas of the brain that are linked to judgment, decision mak-
ing, learning, memory, and behavioral control, which can last long after the period 
of intoxication.
Even though there are no specific biological markers of substance abuse disor-
ders currently on use, there are a number of intriguing neurobiological aspects of 
substance abuse disorders that can help in the diagnosis of substance use, misuse, 
and SUD. An impaired reward system, overactive brain stress systems, and com-
promised orbitofrontal/prefrontal cortex function are some of the major neurobio-
logical changes in the brain revealed in both human and animal studies which are 
quite relevant for the diagnosis of substance use, misuse, and SUD [155]. Although 
addictive substances have common properties, there are still considerable variabili-
ties among classes of drugs in terms of primary and long-term physical and psycho-
logical effects, mechanisms of action, development of tolerance, and withdrawal. 
Differences in the availability, cost, legality, marketing, and cultural attitudes 
towards addictive substances and their use also influence which substances are 
used, and the development of dependence upon them. Thus, the study of substance 
use disorder and addiction must take these factors into account, while at the same 
time noting the similarities across drug classes.
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